Traci Turner

3.7k total citations · 4 hit papers
39 papers, 2.4k citations indexed

About

Traci Turner is a scholar working on Surgery, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Traci Turner has authored 39 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Surgery, 9 papers in Economics and Econometrics and 8 papers in Cancer Research. Recurrent topics in Traci Turner's work include Lipoproteins and Cardiovascular Health (28 papers), Cancer, Lipids, and Metabolism (6 papers) and Pharmaceutical Economics and Policy (6 papers). Traci Turner is often cited by papers focused on Lipoproteins and Cardiovascular Health (28 papers), Cancer, Lipids, and Metabolism (6 papers) and Pharmaceutical Economics and Policy (6 papers). Traci Turner collaborates with scholars based in United States, Netherlands and Canada. Traci Turner's co-authors include Kausik K. Ray, John J.P. Kastelein, David Kallend, R. Scott Wright, Peter Wijngaard, Lawrence A. Leiter, Robert Dufour, Frederick J. Raal, Evan A. Stein and Mahir Karakas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Traci Turner

37 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

2017 738 citations Kausik K. Ray, Ulf Landmesser et al. New England Journal of Medicine profile →
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

2020 562 citations Frederick J. Raal, David Kallend et al. New England Journal of Medicine profile →
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

2014 562 citations Frederick J. Raal, Evan A. Stein et al. The Lancet profile →
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

2022 209 citations Kausik K. Ray, Gerald F. Watts et al. profile →

Peers

Countries citing papers authored by Traci Turner

Since Specialization

Citations

This map shows the geographic impact of Traci Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Traci Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Traci Turner more than expected).

Fields of papers citing papers by Traci Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Traci Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Traci Turner. The network helps show where Traci Turner may publish in the future.

Co-authorship network of co-authors of Traci Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Traci Turner. A scholar is included among the top collaborators of Traci Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Traci Turner. Traci Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zodasiran (ARO-ANG3), an investigational RNAi therapeutic, demonstrates profound and durable reductions in LDL-cholesterol, apolipoprotein B, and ANGPTL3 in patients with HoFH; gateway final results 2025 ·Atherosclerosis ·Frederick J. Raal, (unknown), Daniel Gaudet, (unknown), David Sullivan, Traci Turner, (unknown), (unknown), Jennifer Hellawell, James Hamilton, Robert A. Hegele, Christie M. Ballantyne, Joshua W. Knowles, Ira J. Goldberg, Gerald F. Watts	1
2	Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial 2025 ·The Lancet Diabetes & Endocrinology ·Frederick J. Raal, Vimal Mehta, Meral Kayıkçıoğlu, Dirk Blom, (unknown), Avishay Elis, Traci Turner, Christopher B. Daniels, Jeffrey Vest, Tracy Mitchell, (unknown), El Mustapha Bahassi, David Kallend, Evan A. Stein	6
3	Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 2025 ·The Lancet Diabetes & Endocrinology ·Frederick J. Raal, (unknown), Daniel Gaudet, Robert S. Rosenson, David Sullivan, Traci Turner, Robert A. Hegele, Christie M. Ballantyne, Joshua W. Knowles, Nicholas J. Leeper, Ira J. Goldberg, Rong Zhou, (unknown), Jennifer Hellawell, James Hamilton, Gerald F. Watts	0
4	ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia 2023 ·Atherosclerosis ·Frederick J. Raal, Jean Bergeron, Gerald F. Watts, Daniel Gaudet, David Sullivan, Traci Turner, R A Hegele, Christie M. Ballantyne, Joshua W. Knowles, Ira J. Goldberg, (unknown), (unknown), James Hamilton, Robert S. Rosenson	6
5	Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition 2022 ·European Heart Journal ·Seth S. Martin, (unknown), (unknown), (unknown), Traci Turner, (unknown), John J.P. Kastelein	1
6	EFFICACY AND SAFETY OF A 52 WEEK OPEN LABEL PHASE 2B EXTENSION TRIAL WITH MONTHLY DOSING OF AN ANTI-PCSK9 SMALL BINDING PROTEIN 2020 ·Journal of the American College of Cardiology ·Evan A. Stein, Traci Turner, (unknown), (unknown), Dean J. Kereiakes, Rong Zhou, (unknown), Tracy Mitchell	2
7	Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study 2019 ·Circulation ·Evan A. Stein, Traci Turner, Dean J. Kereiakes, (unknown), (unknown), Rong Zhou	10
8	LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY 2019 ·Journal of the American College of Cardiology ·Evan A. Stein, Traci Turner, (unknown), (unknown), Rong Zhou, (unknown), (unknown), Tracy Mitchell	11
9	DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA VIA CASCADE SCREENING: THE WITS FIND-FH PROGRAM 2018 ·Journal of the American College of Cardiology ·Frederick J. Raal, (unknown), (unknown), (unknown), Gillian J. Pilcher, Matthew L. Kelso, Traci Turner, Evan A. Stein	3
10	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label) 2018 ·Yearbook of pediatric endocrinology ·Marjet J.A.M. Braamskamp, Gisle Langslet, (unknown), David Cassiman, (unknown), C Gagné, Daniel Gaudet, (unknown), Albert Wiegman, Traci Turner, Elinor Miller, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
11	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol breakdown → 2017 ·New England Journal of Medicine ·Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, David Kallend, Robert Dufour, Mahir Karakas, (unknown), Roland P.T. Troquay, Traci Turner, Frank L.J. Visseren, Peter Wijngaard, R. Scott Wright, John J.P. Kastelein	738
12	Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder 2017 ·Mental Health Clinician ·(unknown), Traci Turner, C. Thomas	6
13	Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? 2017 ·Expert Review of Cardiovascular Therapy ·Evan A. Stein, Traci Turner	9
14	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes 2015 ·Clinical Therapeutics ·Traci Turner, Evan A. Stein	22
15	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study 2015 ·Journal of clinical lipidology ·Marjet J.A.M. Braamskamp, Gisle Langslet, Brian W. McCrindle, David Cassiman, Gordon A. Francis, Claude Gagné, Daniel Gaudet, Katherine M. Morrison, Albert Wiegman, Traci Turner, D. Meeike Kusters, Elinor Miller, Joel S. Raichlen, (unknown), Paul Martín, Evan A. Stein, John J.P. Kastelein	33
16	FRIEDEWALD FORMULA SIGNIFICANTLY UNDERESTIMATES LDL CHOLESTEROL COMPARED TO PREPARATIVE ULTRACENTRIFUGATION BELOW 70 MG/DL LEADING TO OVERESTIMATION OF THE LDL CHOLESTEROL REDUCTION FOR NEW DRUGS IN DEVELOPMENT 2014 ·Journal of the American College of Cardiology ·Evan A. Stein, Traci Turner, (unknown), Rong Zhou, (unknown)	5
17	LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY 2014 ·Journal of the American College of Cardiology ·Evan A. Stein, Sreeneeranj Kasichayanula, Traci Turner, (unknown), (unknown), (unknown), J. Jack Lee	44
18	EFFECT OF ROSUVASTATIN THERAPY ON ARTERIAL WALL CHANGES IN CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY 2014 ·Journal of the American College of Cardiology ·Gisle Langslet, Marjet J.A.M. Braamskamp, Brian W. McCrindle, David Cassiman, Gordon Francis, Claude Gagné, Daniel Gaudet, Katherine M. Morrison, Albert Wiegman, Traci Turner, Elinor Miller, Joel S. Raichlen, Paula Martin, Evan A. Stein, John J.P. Kastelein	2
19	EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY 2014 ·Journal of the American College of Cardiology ·Gisle Langslet, Marjet J.A.M. Braamskamp, Brian W. McCrindle, David Cassiman, Gordon A. Francis, Claude Gagné, Daniel Gaudet, Katherine M. Morrison, Albert Wiegman, Traci Turner, Elinor Miller, Joel S. Raichlen, Paula Martin, Paul Martin, Evan A. Stein, J. Kastelein	0
20	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial breakdown → 2014 ·The Lancet ·Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders Olsson, David Sullivan, G. Kees Hovingh, Bertrand Cariou, Ioanna Gouni‐Berthold, Ransi Somaratne, Ian Bridges, Robert C. Scott, Scott M. Wasserman, Daniel Gaudet	562

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact